GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Concord Biotech Ltd (BOM:543960) » Definitions » Net Income From Continuing Operations

Concord Biotech (BOM:543960) Net Income From Continuing Operations : ₹3,716 Mil (TTM As of Mar. 2025)


View and export this data going back to 2023. Start your Free Trial

What is Concord Biotech Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Concord Biotech's net income from continuing operations for the three months ended in Mar. 2025 was ₹1,404 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2025 was ₹3,716 Mil.

Concord Biotech Net Income From Continuing Operations Historical Data

The historical data trend for Concord Biotech's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Concord Biotech Net Income From Continuing Operations Chart

Concord Biotech Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Net Income From Continuing Operations
Get a 7-Day Free Trial 3,127.20 2,375.18 3,220.13 4,125.65 4,945.53

Concord Biotech Quarterly Data
Mar20 Mar21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 950.16 595.93 957.41 759.21 1,403.87

Concord Biotech Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹3,716 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Concord Biotech Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Concord Biotech Ltd (BOM:543960) » Definitions » Net Income From Continuing Operations
Comparable Companies
BOM:544009 BOM:544292 BOM:543434 BOM:540701 BOM:531349 NSE:ZOTA BOM:532067 BOM:500259 BOM:540679 BOM:524717 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
CONCORDBIO:India
Address
Iscon Cross Road, S.G. Highway, B-1601-1602, B-Wing, Mondeal Heights, Ahmedabad, GJ, IND, 380015
Website
https://www.concordbiotech.com
Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products.

Concord Biotech Headlines

No Headlines